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families of the children to better defend their interest before the health authorities
in terms of expenditure (medical or other) for which the part remaining their re-
sponsibility is increasing significantly.
Systemic Disorders/Conditions – Clinical Outcomes Studies
PSY1
SEVERE RENAL, HEPATIC AND GASTROINTESTINAL EVENTS ASSOCIATED
WITH DEFERASIROX IN PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA
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OBJECTIVES: Iron chelators (deferasirox or desferrioxamine) are essential to pa-
tients who need life-long blood transfusion (e.g. -Thalassemia). However, in 2010,
the US Food and Drug Administration (FDA) had issued a warning on potential
adverse events associatedwith iron chelators, especially deferasirox. The objective
of this retrospective cohort study was to compare the risk of renal impairment,
hepatic impairment, and gastrointestinal bleeding in patients with transfusion-
dependent anemia using deferasirox or desferrioxamine.METHODS: Patients with
transfusion-dependent anemia (sickle cell disease, -thalassaemia,myelodysplas-
tic syndrome and aplastic anemia) and were prescribed iron chelators (deferasirox
or desferrioxamine) were identified from the 20052009 Taiwan’s National Health
Insurance database. Cox proportional hazards models were used to assess the
association between iron chelators and occurrences of adverse events (renal im-
pairment, hepatic impairment, and gastrointestinal bleeding). All models adjusted
for age, sex, drug exposure (days), type of transfusion-dependent anemia andmed-
ical history. RESULTS: Patients were categorized into deferasirox (n180), desfer-
rioxamine (n586),and mixed users (n202), based on the drug they received dur-
ing the follow-up. The crude rates of adverse events were 4.14, 3.16 and 0.65 per
10,000 person-year in deferasirox, desferrioxamine and mix users, respectively.
After adjusting covariates, there was no association between deferasirox and ad-
verse events (hazard ratio [HR]0.84; 95% CI, 0.59–2.00) compared to desferrioxam-
ine users. CONCLUSIONS: In this population-based analysis, transfusion-depen-
dant anemia patients using deferasirox and desferrioxaminewere at similar risk of
adverse events.
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THE ASSOCIATION BETWEEN THERAPY WITH ANGIOTENSIN-CONVERTING
ENZYME INHIBITORS AND HEMOGLOBIN LEVEL
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OBJECTIVES: To assess the hematological effects Angiotensin-converting enzyme
(ACE-I) inhibitors and Angiotensin II receptor blockers (ARB) in patients without
concomitant renal impairment. METHODS: In the present retrospective cohort
study we used the Maccabi Healthcare Services’ database to identify new users of
ACE-I (N14754) ARB (N751), or calcium channel blockers (CCB, N3087) with
available hemoglobin (Hb) tests between 2004 and 2009. Excluded were patients
purchasing drugs from more than one medication class, diagnosed with renal im-
pairment or cancer. Median Hb levels one year before and after first medication
purchase (index date)were calculated and compared according to the proportion of
days coveredwithmedication class. RESULTS: Persistent use of ACE-I and ARBwas
associated with a significant decrement in hemoglobin level. Patients at the high-
est PDC level were at a significantly higher risk of developing anemia among ACEI
(OR  1.59, p0.001), and ARB (OR  2.21, p0.05). The relationship between CCB
therapy andHb decrementwas substantially weaker. CONCLUSIONS:Hb levels are
reduced during the first year of ACE-I or ARB therapy. This association is dose-
dependent and is not likely to be caused by artifacts related to patient adherence.
PSY3
OPIOIDS IN NON-MALIGNANT PAIN: ARE THEY EQUIVALENT IN SAFETY
PROFILE? A NETWORK META-ANALYSIS
Siddiqui MK, Gupta J, Bhutani M, Sehgal M
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OBJECTIVES: Severe non-malignant pain affects a large number of patients. Opi-
oids are an important option for analgesia. However, there is relatively little infor-
mation about the comparative safety of opioids. We sought to compare the safety
and tolerability of commonly used opioids in non-malignant pain through network
meta-analyses of randomized controlled trials (RCTs). METHODS: Medline and
Embase were searched from 2000 to 2011 for RCTs comparing commonly used
opioids (tramadol, oxycodone, hydrocodone, propoxyphene, codeine) in non-ma-
lignant pain. Studies were assessed for inclusion/exclusion based on a prespecified
protocol. Two reviewers undertook data extraction independently. Any disagree-
ment was resolved by a third reviewer. A networkmeta-analysis was used to com-
bine direct and indirect evidence for safety outcomes reported in the trials. Based
on the incidence of adverse events (AEs) for each intervention, a probability-based
ranking (probability (P) of beingworst) was generated usingWinBUGS.RESULTS:Of
the 1156 studies, 5 RCTs enrolling 1399 patients were eligible for inclusion. The
most commonly reported AEs were nausea, vomiting, somnolence, dizziness,
headache, constipation and dry mouth. Withdrawals due to AEs were most com-
monly observedwith codeine (P42%) followed by hydrocodone (P28%), tramadol
(P19%), and oxycodone (P10%). The probability of occurrence of nausea and
somnolence was the highest with codeine. Dizziness was most frequently associ-
ated with oxycodone (P 53%). However, the incidence of dizziness and headache
was the lowest with codeine. Tramadol was observed to be associated with the
highest (P40%) incidence of vomiting, while hydrocodone had the lowest inci-
dence (P15%). CONCLUSIONS: Codeinewas observed to have the highest incidence
of withdrawals due to AEs. It was observed that the probability of occurrence of any
particular AE varied across included opioid analgesics. Codeine was observed to have
been more frequently associated with nausea/somnolence while tramadol and oxy-
codone had the highest incidence of vomiting and dizziness respectively.
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OBJECTIVES: Although hyponatremia (HN) is the most common electrolyte abnor-
mality in hospitalized patients, little is known regarding the influence of HN and its
management on patient outcomes and healthcare resource usage. TheHNRegistry
is a novel prospective effort to document the clinical and healthcare outcomes of
HN and its management. Results for the first 25 HN patients enrolled are described
here.METHODS:After informed consent or waiver, data were extracted frommed-
ical charts of enrolled patients. HN was defined as a serum sodium  130 mmol/L.
The pilot data were summarized appropriately by sample size and for categorical
data by percentage. Subjects who had HN on admission were categorized as pre-
existing HN patients and those who were admitted for another reason and devel-
oped HN while in the hospital were categorized as hospital-acquired HN patients.
RESULTS: Overall, only 20% of the enrolled patients received any pharmacologic
management for HN and approximately 44% were discharged with persistent HN
(21% of treated vs. 79% of untreated). Among the patients discharged with HN, 55%
had a previous episode of HN. In addition, among the patients with previous HN,
46% were discharged with persistent HN. The length of stay for patients with pre-
existing HN was 1.3 days longer compared to patients with hospital-acquired HN.
These findings will be further evaluated and reported as more data in this large
registry study are accumulated. CONCLUSIONS:Amonghospitalized patients, HN is
frequently untreated, and nearly half of patients are discharged without normaliza-
tion of serum sodium. HN commonly persists through several hospital admissions.
PSY5
AN INVESTIGATION INTO THE RELATIONSHIP BETWEEN OBESITY AND SKIN
AND SOFT TISSUE INFECTIONS REQUIRING HOSPITALIZATION
Swiney J
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OBJECTIVES: The United States is experiencing an obesity epidemic with 67% of
adults being either overweight or obese. While it is known that excessive weight
increases the opportunity for skin infections, this relationship has not been well
studied. This study contributes to the knowledge about the relationship between
these two conditions.METHODS: Using the H-CUP national database for inpatient
hospitalizations, this study analyzed the data fromhospitals in the Southern states
for the number of skin and soft tissue infections in 2003, 2005 and 2007 in adults.
The proportion of patients who were also coded as obese in this population was
quantified. Two t-tests were performed comparing the average length of stay for
patients who were obese and not obese and the average total hospital charges for
patients who were obese and not obese. Two linear regressions analyzed the im-
pact of obesity on the cost of health care by using length of stay and total hospital
charges as dependent variables. RESULTS: The proportion of patients hospitalized
for skin and soft tissue infections who were also obese increased from 48.09% in
2003 to 51.7% in 2007. The average length of stay was 7.97 days for non-obese
patients verses 4.6 days for patients coded as obese which was statistically signif-
icant. The average total hospital charges were $26,653 for non-obese patients com-
pared to $20,876 for obese patients. This was also statistically significant. Surpris-
ingly, the co-morbidity of obesity has a negative predictive value for both hospital
length of stay and total hospital charges.CONCLUSIONS: It is possible that patients
who are obese are being discharged sooner because of differences in severity of
infections. More research is needed to determinewhether obesity is a causal factor
in skin and soft tissue infections and how this is affecting the cost and delivery of
health care.
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TRANSFUSIONAL IRON OVERLOAD (TIO) MONITORING AND TREATMENT:
FINDINGS FROM AN ELECTRONIC MEDICAL RECORDS REVIEW STUDY AT THE
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OBJECTIVES: We examined proportions of patients: a) monitored for TIO after
receiving 10, 20, and 30 units of red blood cells (RBC) and b) receiving iron
chelation therapy (ICT). We also examined overall survival (OS) among: a) moni-
tored vs. unmonitored; b) ICT-treated vs. ICT-untreated groups.METHODS: Medi-
cal records of patients 18 years receiving 10 RBC units 6 months before data
abstraction were identified at the Moffitt Cancer Center and Research Institute
(December 2009-June 2010). Observation period spanned from 10th RBC unit to end
of follow-up (i.e., death, clinic departure, or end of observation period). TIO moni-
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toring was defined as receipt of1 serum ferritin test after 10th unit. ICT-eligibility
was defined as 2 serum ferritin tests 1,000 g/L or 20 units transfused. ICT
treatment was defined as 1 prescription/administration for deferasirox or defer-
oxamine. Kaplan-Meier and Cox proportional hazards regression methods were
used to compare overall survival. RESULTS: A total of 163 patients were included;
58.3% and 30.1% received20 and30 RBC units, respectively. A total of 50.3% had
leukemia and 20.2% had myelodysplastic syndrome as the underlying disease. A
total of 44.8%, 53.7% and 67.3% of patients receiving 10, 20 and 30 RBC units,
respectively, were monitored for TIO. Compared to unmonitored patients, TIO-
monitored patients had significantly longer median OS (16.13 vs. 2.30 months;
log-rank p-value0.001) even after confounder adjustment (hazards ratio 0.271;
p-value0.001). Among 99 ICT-eligible patients, 9% received ICT; 8 (88.9%) received
deferasirox. Median OS for ICT-treated patients and untreated patients was 9.48
and 7.16 months, respectively (log-rank p-value0.593). CONCLUSIONS: To con-
clude, TIO monitoring after 10 RBC units may be associated with survival benefits,
but 50% of patients receiving 10 transfusions were monitored for TIO. Clinical
benefits of chelating cancer patients have not been established and additional
studies are necessary to ascertain the impact of TIO and chelation utility among
cancer patients.
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A NOVEL MECHANISM OF CAPTURING POST-MARKETING SAFETY
INFORMATION ON RECOMBINANT FACTOR VIIA (RFVIIA) IN THE RARE
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SURVEILLANCE (AHS) PROJECT
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OBJECTIVES: Acquired hemophilia (AH) is a rare disorder (1 per 1.3 million) char-
acterized by auto-antibodies to factor VIII. AH is characterized by life-threatening
bleeding and high mortality. Recombinant factor VIIa (rFVIIa) received FDA ap-
proval for treatment of AH in 2006. As part of the post-approval commitment, Novo
Nordisk agreed to use a society-owned research registry to monitor treatment of
AH bleeding episodes. This required IRB approval and informed consent. For sites
with few patients and/or limited research staff, the registry was not a feasible
option METHODS: An alternative web-based, IRB-exempt reporting method, Ac-
quired Hemophilia Surveillance (AHS, www.novosevensurveillance.com), was es-
tablished to collect data on rFVIIa use in AH and associated adverse events under
the HIPAA safety surveillance waiver. RESULTS: From April 2008-January 2011, 32
reporters submitted 80 case reports (32 male/48 female). The mean age was 65
years (range 16-97). Common associated conditions were autoimmune disorders
(32 patients), malignancy (6 patients) and post-partum state (5 patients). On aver-
age, 5 discrete bleeding events per patient (range 0-100) were reported; 75 case
reports described bleeding as spontaneous (88%), surgical (16%), and/or related to a
procedure (15%). No bypassing agent was reported to have been used in 17 (21%).
rFVIIa was used in 50 (63%), the majority of which were first-line (39, 78%). AH was
reported to have been “resolved” in 44 (55%), “not resolved” in 19 (24%), and “un-
sure” in 16 (20%); mean(median) time to resolution was 7.2(2) months (range 1-52).
There were no reported deaths. None of the 50 rFVIIa-treated cases suffered an
adverse or thrombotic event (AE). CONCLUSIONS: AHS provides an innovative ap-
proach for hemophilia treatment centers and hematology/oncology practices to
capture basic safety surveillance data for patients with Acquired Hemophilia. The
AHSproject provides additional information aboutAH treatment, and reaffirms the
safety of rFVIIa and the low rate of thrombotic complications.
Systemic Disorders/Conditions – Cost Studies
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RELEASE TABLETS
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OBJECTIVES: Compare costs of privately-insured oxymorphone extended-release
tablet (“oxymorphone”) users with those of oxycodone controlled-release tablet
(“oxycodone”) users, from an employer’s perspective. METHODS: Patients, ages
18, with 1 claim for oxymorphone/oxycodone during Q2:2006-Q4:2009 were
identified in de-identified private payer claims data and observed from the first
such claim (“index date”) until the earliest of: use of comparator drug; end of
continuous eligibility; or 12 months (“study period”). Continuous eligibility was
required throughout a 6-month baseline period and1month after the index date.
Patients with claims for any formulation (extended-release or otherwise) of the
comparator drug during the first 30 days of the study periodwere excluded, aswere
patients pregnant during the baseline/study periods. Study period risk-adjusted
costs were estimated per patient-month using generalized estimating equations
controlling for baseline demographics, resource use, and costs. Medical/drug (di-
rect) costs paid by private insurers were reported for patients ages 18-64 (N 8,354)
and 65 (N  3,515) as well as subsets of each without cancer during the baseline/
study periods (N  7,090 and N  2,444, respectively). Medically-related absentee-
ism and disability (indirect) costs were reported for all employees, ages 18-64, (N
1,313) and employeeswithout cancer (N 1,146). Bias-corrected bootstrappingwas
used to compare third-party payer costs. RESULTS: Oxymorphone users, ages 18-
64, had lower drug costs ($693 vs. $763, p0.0035) and similar medical costs ($1,875
vs. $1,976, p0.3570) per patient-month compared with oxycodone users. Indirect
costs were not different ($662 vs. $670, p0.9370). Oxymorphone users, ages 65,
had similar Medicare supplemental drug costs ($533 vs. $588, p0.0840) and signif-
icantly lower medical costs ($459 vs. $747, p0.0001). Results were comparable for
the subsets without cancer. CONCLUSIONS: After controlling for baseline charac-
teristics, real-world evidence suggests that, from an employer’s perspective, oxy-
morphone users may incur lower monthly direct costs than oxycodone users.
PSY9
HEALTH CONSEQUENCES AND COSTS OF TACHOSIL® AS HAEMOSTATIC
TREATMENT IN LIVER SURGERY VERSUS TISSUCOL®: A RETROSPECTIVE
OBSERVATIONAL COHORT STUDY
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OBJECTIVES: The objective of this study was to compare the effectiveness and
costs of TachoSil® carrier-bound collagen sponges versus Tissucol® fibrin glue in
patients undergoing liver surgery in current medical practice.METHODS: A retro-
spective observational cohort study was carried out including 244 patients (128 in
TachoSil® group and 116 in Tissucol® group) that underwent a liver surgery a
university hospital. Data on demographics, medical background, effectiveness, re-
source consumption and complicationswere obtained by reviewing patients=med-
ical records. Unit costs were obtained from financial hospital records and drug
costs from the Spanish health authorities. Collection of patient data took place
from definitive surgery until hospital discharge using a hospital=s perspective.
Variables collected to estimate costs and effectiveness were haemostatic drugs,
surgical time, drainage, blood transfusions and hospitalisation days. Research out-
comes were presented as the differences in effectiveness measures and costs for
the collected variables using statistical analysis (p0.05).RESULTS:WithTachoSil®
significantly less patients required a drainage (12.5% vs. 52.6%, p0.001) and pa-
tients were hospitalized for a minor number of days (median 6 vs. 8 days,
p0.00013). No statistical differences between both groups were observed in the
rest of the effectiveness data pre- and postoperative. The TachoSil® group showed
significant lower mean costs with respect to haemostatic drugs (mean [SD] euro,
974€ [787€] vs. 987€ [384€], p0.03) and drainage (3€ [7€] vs. 12€ [11€], p0.00). No
significant differences in other costs between both treatments were reported.
CONCLUSIONS: TachoSil® showed to reduce drainage and hospitalisation days.
However no significant lower total costs for the TachoSil® group (10,212€ [8,197€])
vs. the Tissucol® group (10,224€ [7,394€]) could be demonstrated.
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OBJECTIVES: Spaepen et al. (the Oncologist 2008;13:596–607) published a cost-
analysis comparing darbepoetin alfa (DARB), epoetin alfa (EPO-A) and epoetin beta
(EPO-B) in the treatment of chemotherapy-induced anemia, using propensity score
matching. The study was performed using the IMS Hospital Disease Database, a
longitudinal database unique to Belgium containing individual patient/admission-
level data on diagnoses, procedures, and pharmaceuticals. Given the limited avail-
ability of other databases reporting the same level of information in other Euro-
pean countries, the objectives of this study were to assess the applicability of the
Belgian analysis, and to estimate differences in costs between ESAs in Austria,
Italy, Portugal, and Spain. METHODS: To adapt the analysis, costs were replaced
with country-specific costs and discrepancies in epidemiology and treatment pat-
terns were examined. Adjusting for country discrepancies, costs were analyzed
using a mixed-effects model stratifying for propensity score quintiles as in Spa-
epen 2008. Sources included Eurostat, national cancer registries, IMS sales data,
and reimbursement and treatment guidelines for procedures and drugs. RESULTS:
All populations were comparable to Belgium in terms of age, gender, ESA use, and
blood transfusions. Adjusting for chemotherapy use and tumor-specific cancer
incidence, total costs (Euro, 2010)withDARBwere 22-26% lower compared to EPO-A
and 20-35% lower compared to EPO-B. Anemia-related costs were lowest for DARB
€2,585154, EPO-A €3,10299, EPO-B €2,969166 in Austria; DARB €3,144211,
EPO-A €5,049119, EPO-B €3,656230 in Italy; DARB €2,153117, EPO-A €2,44663,
EPO-B €2,654124 in Portugal; and DARB €2,378143, EPO-A €3,34975, EPO-B
€2,857153 in Spain. CONCLUSIONS: Total and anemia-related costs were lowest
in patients receiving DARB compared to EPO-A or EPO-B in all countries. Although
it was not possible to account for all differences among countries, the findings are
in line with those from the Belgian analysis, and demonstrate the feasibility of
adapting such data to other settings accounting for patient characteristics and
treatment costs.
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BURDEN OF ILLNESS IN FIBROMYALGIA SYNDROME: THE PATIENTS’
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